Literature DB >> 21935972

Evaluation of genotoxicity induced by exposure to antineoplastic drugs in lymphocytes of oncology nurses and pharmacists.

Ahmad A El-Ebiary1, Arwa A Abuelfadl, Naglaa I Sarhan.   

Abstract

The hazards of handling antineoplastic drugs have been raised and discussed in several studies. Introduction of new antineoplastics together with abuse of safety standards have contributed to the exposure risk for personnel who handle these substances. Interactions of antineoplastic drugs with biological structures vary according to the drug(s) and the individual's genetic susceptibility. This study was carried out to evaluate the genome damage induced by exposure to antineoplastic drugs in nurses (n = 20) and pharmacists (n = 18) working in the Oncology Department of Tanta Cancer Center. Thirty subjects matched in age, gender and smoking habit were selected as controls. Both chromosomal aberration analysis and micronucleus assay were used to evaluate genome damage in peripheral blood lymphocytes of the study subjects. The numbers of aberrant lymphocytes, as well as chromosomal aberration and micronuclei frequencies, were significantly increased in exposed personnel in comparison to matched controls. Compared with pharmacists, nurses showed notably higher level of chromosome damage. On the other hand, no significant difference in micronuclei frequency was observed between nurses and pharmacists. Correlation analyses pointed to the influence of age and duration of occupational exposure on the level of chromosome damage among exposed subjects. The results of this study confirmed that handling antineoplastic drugs without appropriate precautions imposed a genotoxic risk for exposed healthcare workers. These results address the need for regular biomonitoring of exposed personnel. In addition, they call attention to the need for proper implementation of intervention measures aiming to eliminate or significantly reduce worker exposure and prevent untoward biological effects.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21935972     DOI: 10.1002/jat.1735

Source DB:  PubMed          Journal:  J Appl Toxicol        ISSN: 0260-437X            Impact factor:   3.446


  6 in total

1.  Micronuclei and chromosome aberrations in subjects occupationally exposed to antineoplastic drugs: a multicentric approach.

Authors:  Massimo Moretti; Maria Giuseppa Grollino; Sofia Pavanello; Roberta Bonfiglioli; Milena Villarini; Massimo Appolloni; Mariella Carrieri; Laura Sabatini; Luca Dominici; Laura Stronati; Giuseppe Mastrangelo; Anna Barbieri; Cristina Fatigoni; Giovanni Battista Bartolucci; Elisabetta Ceretti; Francesca Mussi; Silvano Monarca
Journal:  Int Arch Occup Environ Health       Date:  2014-11-02       Impact factor: 3.015

Review 2.  Applicability of the comet assay in evaluation of DNA damage in healthcare providers' working with antineoplastic drugs: a systematic review and meta-analysis.

Authors:  Mohammad Javad Zare Sakhvidi; Mohammad Hajaghazadeh; Mehrdad Mostaghaci; Amir Houshang Mehrparvar; Fariba Zare Sakhvidi; Elham Naghshineh
Journal:  Int J Occup Environ Health       Date:  2016-04-25

Review 3. 

Authors:  Céline Poupeau; Christel Roland; Jean-François Bussières
Journal:  Can J Hosp Pharm       Date:  2016-10-31

4.  Genotoxic evaluation of occupational exposure to antineoplastic drugs.

Authors:  Andres Felipe Aristizabal-Pachon; Willian Orlando Castillo
Journal:  Toxicol Res       Date:  2019-12-02

Review 5.  Meta-analysis of chromosomal aberrations as a biomarker of exposure in healthcare workers occupationally exposed to antineoplastic drugs.

Authors:  Christine Roussel; Kristine L Witt; Peter B Shaw; Thomas H Connor
Journal:  Mutat Res Rev Mutat Res       Date:  2017-08-24       Impact factor: 5.657

Review 6.  DNA damage and repair in human cancer: molecular mechanisms and contribution to therapy-related leukemias.

Authors:  Ida Casorelli; Cecilia Bossa; Margherita Bignami
Journal:  Int J Environ Res Public Health       Date:  2012-07-27       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.